TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06746883: A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection

Sponsor: Innoviva Specialty Therapeutics · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 100 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$1,440,600

Rescue Site Savings

+$940,800

Unlock Full NCT06746883 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06746883 Rescue Dossier →